The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment
A growing body of evidence suggests that a major subset of patients with advanced solid tumors shows evidence for a T-cell-inflamed tumor microenvironment. This phenotype has positive prognostic value for several types of early stage cancer, suggesting that the attempt by the host to generate an ant...
Saved in:
| Published in: | Seminars in oncology Vol. 42; no. 4; pp. 663 - 671 |
|---|---|
| Main Author: | |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
01.08.2015
|
| Subjects: | |
| ISSN: | 1532-8708 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | A growing body of evidence suggests that a major subset of patients with advanced solid tumors shows evidence for a T-cell-inflamed tumor microenvironment. This phenotype has positive prognostic value for several types of early stage cancer, suggesting that the attempt by the host to generate an anti-tumor immune response reflects a biologic process associated with improved patient outcomes. In metastatic disease, the presence of this phenotype appears to be associated with clinical response to several immunotherapies, including cancer vaccines, checkpoint blockade, and adoptive T-cell transfer. With the high rate of clinical response to several of these therapies, along with early data indicating that combination immunotherapies may be even more potent, it seems likely that effective immune-based therapies will become a reality for patients with a range of different cancers that physiologically support the T-cell-inflamed tumor microenvironment in a subset of individuals. Therefore, one of the next significant hurdles will be to develop new therapeutic interventions that will enable these immunotherapies to be effective in patients with the non-T-cell-inflamed phenotype. Rational development of such interventions will benefit from a detailed molecular understanding of the mechanisms that explain the presence or absence of the T-cell-inflamed tumor microenvironment, which in turn will benefit from focused interrogation of patient samples. This iterative "reverse-translational" research strategy has already identified new candidate therapeutic targets and approaches. It is envisioned that the end result of these investigations will be an expanded array of interventions that will broaden the fraction of patients benefitting from immunotherapies in the clinic. |
|---|---|
| AbstractList | A growing body of evidence suggests that a major subset of patients with advanced solid tumors shows evidence for a T-cell-inflamed tumor microenvironment. This phenotype has positive prognostic value for several types of early stage cancer, suggesting that the attempt by the host to generate an anti-tumor immune response reflects a biologic process associated with improved patient outcomes. In metastatic disease, the presence of this phenotype appears to be associated with clinical response to several immunotherapies, including cancer vaccines, checkpoint blockade, and adoptive T-cell transfer. With the high rate of clinical response to several of these therapies, along with early data indicating that combination immunotherapies may be even more potent, it seems likely that effective immune-based therapies will become a reality for patients with a range of different cancers that physiologically support the T-cell-inflamed tumor microenvironment in a subset of individuals. Therefore, one of the next significant hurdles will be to develop new therapeutic interventions that will enable these immunotherapies to be effective in patients with the non-T-cell-inflamed phenotype. Rational development of such interventions will benefit from a detailed molecular understanding of the mechanisms that explain the presence or absence of the T-cell-inflamed tumor microenvironment, which in turn will benefit from focused interrogation of patient samples. This iterative "reverse-translational" research strategy has already identified new candidate therapeutic targets and approaches. It is envisioned that the end result of these investigations will be an expanded array of interventions that will broaden the fraction of patients benefitting from immunotherapies in the clinic. |
| Author | Gajewski, Thomas F |
| Author_xml | – sequence: 1 givenname: Thomas F surname: Gajewski fullname: Gajewski, Thomas F email: tgajewsk@medicine.bsd.uchicago.edu organization: Department of Pathology and Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, IL. Electronic address: tgajewsk@medicine.bsd.uchicago.edu |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26320069$$D View this record in MEDLINE/PubMed |
| BookMark | eNo1kEtPwzAQhC0Eog_4C8hHLgn2Js6DG4qAVir0Es6R7WxoqtguTlLRf08QRVpppNU3u6NZkEvrLBJCOQs5E9HDPuzRtNNSuy4ExkXIpuH8gsy5iCDIUpbNyKLv94wBTwGuyQySCBhL8jlR5Q7pO34PdDX6ukPaWlpIq9HTtTGjdcMOvTycHun2iF676dMnHX49zgZlUGDXBWvbdNJgTcvROE_fWu0d2mPrnTVohxty1ciux9uzLsnHy3NZrILN9nVdPG0CLYAPgcZMpTGIRtQyz3Ooo4ZnIGuZNQAQxwriKNVMJHmimZINRFksOc-VSoRqQMCS3P_dPXj3NWI_VKbt9RRQWnRjX_GpiCxPIPlF787oqKbg1cG3RvpT9d8L_AAOI2gw |
| CitedBy_id | crossref_primary_10_1093_annonc_mdw217 crossref_primary_10_1186_s13071_022_05456_8 crossref_primary_10_1080_14712598_2020_1733965 crossref_primary_10_1007_s00432_022_04474_4 crossref_primary_10_1002_adma_202211130 crossref_primary_10_1016_j_therap_2021_06_005 crossref_primary_10_1158_1078_0432_CCR_16_1433 crossref_primary_10_3390_cancers14225676 crossref_primary_10_3389_fimmu_2023_1230534 crossref_primary_10_1016_j_imlet_2020_11_003 crossref_primary_10_1177_1758835918786658 crossref_primary_10_1002_adfm_202306930 crossref_primary_10_1186_s12943_018_0814_0 crossref_primary_10_1158_1078_0432_CCR_17_0189 crossref_primary_10_1186_s12885_022_09349_y crossref_primary_10_3389_fcell_2021_736298 crossref_primary_10_1111_imr_12982 crossref_primary_10_3389_fonc_2021_773420 crossref_primary_10_3390_cancers13081830 crossref_primary_10_3892_ol_2024_14670 crossref_primary_10_3390_cancers11101578 crossref_primary_10_1155_2022_2910491 crossref_primary_10_1002_kjm2_12375 crossref_primary_10_1158_2159_8290_CD_18_0099 crossref_primary_10_3390_ijms20081903 crossref_primary_10_1038_s41598_018_30417_6 crossref_primary_10_3389_fcell_2021_769409 crossref_primary_10_3390_genes12101535 crossref_primary_10_3389_fimmu_2023_1095943 crossref_primary_10_1002_mc_23188 crossref_primary_10_1073_pnas_1818210116 crossref_primary_10_3389_fcell_2022_791630 crossref_primary_10_1016_j_jconrel_2019_04_008 crossref_primary_10_1245_s10434_019_07815_9 crossref_primary_10_1158_1078_0432_CCR_16_3186 crossref_primary_10_1016_j_bbadis_2024_167345 crossref_primary_10_1126_science_aad4140 crossref_primary_10_1155_2022_9451480 crossref_primary_10_1172_JCI125413 crossref_primary_10_1038_s41392_021_00658_5 crossref_primary_10_3389_fimmu_2019_01835 crossref_primary_10_1002_smll_202411474 crossref_primary_10_1146_annurev_immunol_070621_030155 crossref_primary_10_20517_cdr_2024_206 crossref_primary_10_1007_s12026_015_8734_1 crossref_primary_10_3389_fonc_2022_880876 crossref_primary_10_1038_s41374_021_00653_y crossref_primary_10_1158_1078_0432_CCR_18_1550 crossref_primary_10_1021_acscentsci_4c00579 crossref_primary_10_3389_fphar_2024_1365683 crossref_primary_10_3389_fonc_2022_1093240 crossref_primary_10_1038_s41571_024_00984_x crossref_primary_10_3389_fonc_2019_01185 crossref_primary_10_1002_adbi_202400434 crossref_primary_10_1200_JCO_2017_72_8089 crossref_primary_10_1158_1078_0432_CCR_15_1849 crossref_primary_10_1007_s11888_017_0347_8 crossref_primary_10_1016_j_coms_2018_09_002 crossref_primary_10_1038_nprot_2017_130 crossref_primary_10_1158_2326_6066_CIR_15_0274 crossref_primary_10_1016_j_immuni_2018_03_037 crossref_primary_10_1016_j_smim_2016_01_002 crossref_primary_10_1371_journal_pbio_3000591 crossref_primary_10_1038_s41401_020_0423_5 crossref_primary_10_1002_wsbm_1539 crossref_primary_10_1038_s41598_021_90538_3 crossref_primary_10_1016_j_xcrm_2025_102141 crossref_primary_10_1186_s13027_018_0206_5 crossref_primary_10_2174_1381612825666190708214240 crossref_primary_10_1016_j_trsl_2021_12_001 crossref_primary_10_3389_fonc_2021_734873 crossref_primary_10_3389_fimmu_2017_01993 crossref_primary_10_1080_2162402X_2016_1267891 crossref_primary_10_1186_s40246_023_00469_5 crossref_primary_10_1002_ijc_33237 crossref_primary_10_1016_j_tranon_2024_102055 crossref_primary_10_3389_fimmu_2021_754436 crossref_primary_10_3390_pharmaceutics14112429 crossref_primary_10_3390_ijms20010024 crossref_primary_10_1371_journal_pone_0274704 crossref_primary_10_3389_fcell_2021_800967 crossref_primary_10_1186_s13045_017_0471_6 crossref_primary_10_7717_peerj_19121 crossref_primary_10_3389_fonc_2021_626818 crossref_primary_10_3389_fimmu_2021_713001 crossref_primary_10_3389_fonc_2023_972558 crossref_primary_10_1038_s41598_023_37300_z crossref_primary_10_1016_j_imlet_2024_106938 crossref_primary_10_18632_oncotarget_17397 crossref_primary_10_3389_fphar_2023_1103547 crossref_primary_10_3390_cancers15010109 crossref_primary_10_1158_0008_5472_CAN_17_1340 crossref_primary_10_1158_1078_0432_CCR_15_1507 crossref_primary_10_1158_1078_0432_CCR_19_0289 crossref_primary_10_1016_j_nantod_2019_100766 crossref_primary_10_1126_scitranslmed_aar1916 crossref_primary_10_1155_2020_9350272 crossref_primary_10_1038_s41568_019_0186_9 crossref_primary_10_3389_fimmu_2021_663495 crossref_primary_10_3390_cells12060926 crossref_primary_10_1158_1078_0432_CCR_20_3944 crossref_primary_10_1186_s40537_022_00641_z crossref_primary_10_1038_s41586_023_06132_2 crossref_primary_10_3390_cancers12123828 crossref_primary_10_1111_bph_15222 crossref_primary_10_1186_s40425_017_0243_4 crossref_primary_10_3390_cancers13123083 crossref_primary_10_3389_fimmu_2024_1395035 crossref_primary_10_1007_s11864_021_00891_8 crossref_primary_10_1186_s12935_021_02423_8 crossref_primary_10_3389_fonc_2022_960734 crossref_primary_10_1155_2023_1189022 crossref_primary_10_3390_cancers16051021 crossref_primary_10_3389_fonc_2023_1037884 crossref_primary_10_1007_s00262_024_03732_3 crossref_primary_10_1136_jitc_2020_000710 crossref_primary_10_3390_cancers17060994 crossref_primary_10_1158_1078_0432_CCR_18_0261 crossref_primary_10_3390_jpm11010053 crossref_primary_10_1016_j_urolonc_2018_10_011 crossref_primary_10_1186_s12885_020_6545_9 crossref_primary_10_1155_2022_8766735 crossref_primary_10_1002_smll_202006231 crossref_primary_10_1038_s41598_025_11590_x crossref_primary_10_1111_imm_13562 crossref_primary_10_3390_cancers14174246 crossref_primary_10_1038_s41573_018_0011_2 crossref_primary_10_3389_fonc_2021_611115 crossref_primary_10_2217_imt_2016_0145 crossref_primary_10_1126_scitranslmed_aad7661 crossref_primary_10_3390_ijms21207743 crossref_primary_10_1158_0008_5472_CAN_19_1167 crossref_primary_10_1007_s12307_019_00233_1 crossref_primary_10_3390_ijms22073374 crossref_primary_10_3390_vaccines8040617 crossref_primary_10_1038_s41467_017_01830_8 crossref_primary_10_1080_15592294_2022_2160134 crossref_primary_10_1007_s12672_024_00945_x crossref_primary_10_1158_2326_6066_CIR_18_0214 crossref_primary_10_1016_j_semcancer_2018_05_001 crossref_primary_10_1186_s12575_022_00177_9 crossref_primary_10_3390_arm92060045 crossref_primary_10_1002_lio2_235 crossref_primary_10_1038_s41568_018_0009_4 crossref_primary_10_3389_fimmu_2023_1084887 crossref_primary_10_3389_fcell_2022_842835 crossref_primary_10_1186_s12915_025_02237_4 crossref_primary_10_23736_S0393_3660_24_05570_0 crossref_primary_10_1007_s00432_023_04589_2 crossref_primary_10_1172_JCI79434 crossref_primary_10_3389_fonc_2022_927298 crossref_primary_10_3390_cancers13235911 crossref_primary_10_1016_j_jneuroim_2024_578402 crossref_primary_10_1158_1078_0432_CCR_18_1932 crossref_primary_10_1159_000510385 crossref_primary_10_3389_fonc_2021_690129 crossref_primary_10_1080_17512433_2018_1518713 crossref_primary_10_1093_annonc_mdw226 crossref_primary_10_13181_mji_v28i4_3211 crossref_primary_10_3390_cancers11091400 crossref_primary_10_1158_1078_0432_CCR_16_1860 crossref_primary_10_1038_s41418_018_0214_4 crossref_primary_10_1038_s41572_025_00603_8 crossref_primary_10_1016_j_ijrobp_2020_04_023 crossref_primary_10_1073_pnas_1914906117 crossref_primary_10_1158_2326_6066_CIR_18_0226 crossref_primary_10_1038_nature21349 crossref_primary_10_3389_fimmu_2022_978195 crossref_primary_10_1016_j_neo_2023_100892 crossref_primary_10_1186_s40425_017_0299_1 crossref_primary_10_1038_s41467_018_05992_x crossref_primary_10_1126_sciimmunol_aag1266 crossref_primary_10_1016_j_oraloncology_2020_104928 crossref_primary_10_1186_s41065_023_00263_2 crossref_primary_10_1016_j_hoc_2018_12_006 crossref_primary_10_3892_ol_2019_10166 crossref_primary_10_1002_ijc_32061 crossref_primary_10_1007_s10238_023_01201_2 crossref_primary_10_1186_s12859_016_1141_3 crossref_primary_10_3390_targets3020021 crossref_primary_10_1007_s10456_021_09819_0 crossref_primary_10_1038_nm_4200 crossref_primary_10_1016_j_coi_2021_02_001 crossref_primary_10_3389_fcell_2021_739161 crossref_primary_10_1007_s00262_017_2114_8 crossref_primary_10_1007_s00262_017_1966_2 crossref_primary_10_1016_j_bmcl_2022_128947 crossref_primary_10_1080_2162402X_2017_1320626 crossref_primary_10_1007_s00262_023_03433_3 crossref_primary_10_1016_j_abb_2022_109168 crossref_primary_10_3389_fgene_2022_1029576 crossref_primary_10_3390_jcm8111989 crossref_primary_10_1016_j_clon_2018_01_001 crossref_primary_10_1038_s41467_024_52104_z crossref_primary_10_1016_j_biocel_2022_106309 crossref_primary_10_1126_science_adr3026 crossref_primary_10_1016_j_tranon_2021_101047 crossref_primary_10_1186_s12885_022_09840_6 crossref_primary_10_1136_jitc_2021_002715 crossref_primary_10_1038_s41417_021_00389_3 crossref_primary_10_3390_cancers12113123 crossref_primary_10_1002_ijc_34021 crossref_primary_10_1016_j_jtbi_2023_111593 crossref_primary_10_3389_fphar_2023_1261575 crossref_primary_10_3390_vaccines4040037 crossref_primary_10_31083_j_fbl2806130 crossref_primary_10_4049_jimmunol_1700529 crossref_primary_10_1186_s13048_025_01589_3 crossref_primary_10_3390_md20110667 crossref_primary_10_1158_1078_0432_CCR_18_1038 crossref_primary_10_2139_ssrn_3811836 crossref_primary_10_1186_s12876_022_02475_8 crossref_primary_10_1038_s41571_018_0142_8 crossref_primary_10_1172_JCI171154 crossref_primary_10_1126_scitranslmed_abb3631 crossref_primary_10_3748_wjg_v24_i32_3583 crossref_primary_10_1016_j_canlet_2020_10_041 crossref_primary_10_1007_s10735_021_09967_z crossref_primary_10_1016_j_annonc_2021_10_009 crossref_primary_10_3389_fmolb_2022_951636 crossref_primary_10_3390_jcm11247523 crossref_primary_10_1002_jhbp_944 crossref_primary_10_1016_j_ctrv_2020_101977 crossref_primary_10_3390_ijms23063218 crossref_primary_10_1016_j_phrs_2024_107063 crossref_primary_10_3389_fonc_2017_00024 crossref_primary_10_1097_PPO_0000000000000368 crossref_primary_10_1186_s12885_024_12790_w crossref_primary_10_1080_2162402X_2017_1356153 crossref_primary_10_4049_jimmunol_1901172 crossref_primary_10_1016_j_adcanc_2023_100107 crossref_primary_10_1016_j_oraloncology_2022_105860 crossref_primary_10_1038_s41598_021_04678_7 crossref_primary_10_1126_scitranslmed_aaf0685 crossref_primary_10_1038_s41379_018_0019_5 crossref_primary_10_3390_ijms21020556 crossref_primary_10_1016_j_intimp_2021_108007 crossref_primary_10_1158_1078_0432_CCR_16_0049 crossref_primary_10_1002_cam4_6080 crossref_primary_10_1016_j_apsb_2020_03_001 crossref_primary_10_3389_fonc_2021_681629 crossref_primary_10_3389_fonc_2020_568279 crossref_primary_10_3389_fonc_2020_01438 crossref_primary_10_1007_s00262_017_1954_6 crossref_primary_10_1016_j_smim_2018_02_003 crossref_primary_10_1136_jitc_2020_002195 crossref_primary_10_1038_s41591_019_0596_y crossref_primary_10_1158_1078_0432_CCR_23_1530 crossref_primary_10_1016_j_biopha_2022_113084 crossref_primary_10_1136_jitc_2023_006773 crossref_primary_10_2147_JIR_S356841 crossref_primary_10_1186_s12943_019_1074_3 crossref_primary_10_1002_hed_27340 crossref_primary_10_1038_s41571_021_00496_y crossref_primary_10_1080_2162402X_2020_1824631 crossref_primary_10_1073_pnas_1904253116 crossref_primary_10_1016_j_omto_2021_06_011 crossref_primary_10_1186_s40425_017_0308_4 crossref_primary_10_1038_mto_2016_34 crossref_primary_10_1007_s12094_024_03742_8 crossref_primary_10_3389_fimmu_2021_722479 crossref_primary_10_1016_j_ymthe_2023_11_026 crossref_primary_10_3390_cancers13194906 crossref_primary_10_4251_wjgo_v15_i2_240 crossref_primary_10_1186_s12943_020_01170_0 crossref_primary_10_1016_j_ctrv_2024_102848 crossref_primary_10_1038_s41541_020_0201_x crossref_primary_10_1111_1754_9485_13399 crossref_primary_10_1136_jitc_2024_010928 crossref_primary_10_1136_jitc_2020_000563 crossref_primary_10_1007_s11095_018_2438_x crossref_primary_10_1016_j_oraloncology_2017_05_002 crossref_primary_10_1038_s41416_023_02432_6 crossref_primary_10_1186_s40824_023_00389_4 crossref_primary_10_1080_14712598_2020_1713086 crossref_primary_10_1186_s40164_024_00543_1 crossref_primary_10_1136_jitc_2023_007230 crossref_primary_10_1084_jem_20181739 crossref_primary_10_3389_fimmu_2022_986785 crossref_primary_10_1016_j_ygyno_2020_04_689 crossref_primary_10_1038_s41416_020_01070_6 crossref_primary_10_1016_j_pharmthera_2017_03_008 crossref_primary_10_4049_jimmunol_2300111 crossref_primary_10_1186_s12967_022_03355_1 crossref_primary_10_1007_s12032_023_02021_w crossref_primary_10_1038_srep26345 crossref_primary_10_1136_jitc_2022_006533 crossref_primary_10_1016_j_urolonc_2016_10_006 crossref_primary_10_3389_fimmu_2021_763888 crossref_primary_10_1038_s41565_019_0512_0 crossref_primary_10_1158_0008_5472_CAN_19_0267 crossref_primary_10_3389_fimmu_2024_1333923 crossref_primary_10_1158_1078_0432_CCR_17_0019 crossref_primary_10_3892_ijo_2022_5378 crossref_primary_10_2217_imt_2017_0067 crossref_primary_10_1080_2162402X_2018_1445459 crossref_primary_10_1016_j_apsb_2019_09_006 crossref_primary_10_1016_j_drup_2019_100646 crossref_primary_10_1016_j_cyto_2018_04_006 crossref_primary_10_1002_advs_202300110 crossref_primary_10_3389_fimmu_2025_1625813 crossref_primary_10_1002_advs_202100166 crossref_primary_10_1002_advs_202103677 crossref_primary_10_3390_nano9101455 crossref_primary_10_2147_OTT_S282763 crossref_primary_10_3389_fonc_2023_1291720 crossref_primary_10_1016_S1470_2045_17_30624_1 crossref_primary_10_1080_2162402X_2021_2005280 crossref_primary_10_1093_jnci_djaa021 crossref_primary_10_1186_s40425_017_0223_8 crossref_primary_10_1097_PPO_0000000000000327 crossref_primary_10_3389_fimmu_2019_00333 crossref_primary_10_3389_fimmu_2019_00698 crossref_primary_10_1186_s12885_025_13982_8 crossref_primary_10_1016_j_clsc_2017_09_001 crossref_primary_10_1002_adfm_202002299 crossref_primary_10_1038_s41590_018_0290_0 crossref_primary_10_1002_advs_202413181 crossref_primary_10_1039_C9NR04418C crossref_primary_10_3390_biomedicines10102498 crossref_primary_10_1016_j_jconrel_2018_09_009 crossref_primary_10_3389_fonc_2020_600573 crossref_primary_10_1016_j_ymthe_2018_09_005 crossref_primary_10_1172_JCI93303 crossref_primary_10_1634_theoncologist_2017_0354 crossref_primary_10_1016_j_tranon_2025_102291 crossref_primary_10_1158_2326_6066_CIR_17_0519 crossref_primary_10_3389_fcell_2021_781848 crossref_primary_10_1098_rsos_211991 crossref_primary_10_3389_fimmu_2024_1498942 crossref_primary_10_1080_23808993_2016_1140005 crossref_primary_10_1111_bju_15324 crossref_primary_10_1007_s12672_025_03316_2 crossref_primary_10_1016_j_it_2020_03_003 crossref_primary_10_1038_s12276_024_01332_w crossref_primary_10_1053_j_seminoncol_2016_06_008 crossref_primary_10_1158_2326_6066_CIR_16_0309 crossref_primary_10_1182_blood_2016_03_705780 crossref_primary_10_1016_j_csbj_2021_08_005 crossref_primary_10_1016_j_diii_2017_12_011 crossref_primary_10_3390_mi13122217 crossref_primary_10_3389_fimmu_2022_933241 crossref_primary_10_3389_fgene_2022_818378 crossref_primary_10_1186_s13045_023_01430_8 |
| ContentType | Journal Article |
| Copyright | Copyright © 2015 Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: Copyright © 2015 Elsevier Inc. All rights reserved. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1053/j.seminoncol.2015.05.011 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1532-8708 |
| EndPage | 671 |
| ExternalDocumentID | 26320069 |
| Genre | Journal Article Review |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: R01 CA181160 – fundername: NCI NIH HHS grantid: R01 CA198496 – fundername: NCI NIH HHS grantid: R01 CA161005 – fundername: NCI NIH HHS grantid: R01 CA127475 |
| GroupedDBID | --- --K .1- .55 .FO .GJ 0R~ 123 1P~ 3O- 4.4 457 4CK 53G 5RE AAEDW AALRI AAQOH AAQQT AAQXK AAWTL AAXUO ABFRF ABJNI ABOCM ABUDA ABWVN ACGFO ACRPL ADBBV ADMUD ADNMO AEFWE AENEX AEVXI AFCTW AFETI AFFNX AFJKZ AFRHN AFTJW AGHFR AGQPQ AGRDE AIGII AITUG AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP ASPBG AVWKF AZFZN CGR CS3 CUY CVF DU5 EBS ECM EIF EJD F5P FDB FEDTE FGOYB GBLVA HVGLF HZ~ IH2 J5H K-O L7B MJL N4W NPM O9- OC~ OO- P2P R2- RIG ROL SEL SES SJN TWZ UDS X7M Z5R ZGI ZXP 7X8 |
| ID | FETCH-LOGICAL-c521t-ce8b7425f5da9992d3f182ada8f22244b2437c05696c0baf2384a119bb65bf252 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 405 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000360782200014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| IngestDate | Thu Oct 02 07:47:39 EDT 2025 Mon Jul 21 06:05:07 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| License | Copyright © 2015 Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c521t-ce8b7425f5da9992d3f182ada8f22244b2437c05696c0baf2384a119bb65bf252 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| OpenAccessLink | http://doi.org/10.1053/j.seminoncol.2015.05.011 |
| PMID | 26320069 |
| PQID | 1708896265 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_1708896265 pubmed_primary_26320069 |
| PublicationCentury | 2000 |
| PublicationDate | 2015-08-01 |
| PublicationDateYYYYMMDD | 2015-08-01 |
| PublicationDate_xml | – month: 08 year: 2015 text: 2015-08-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Seminars in oncology |
| PublicationTitleAlternate | Semin Oncol |
| PublicationYear | 2015 |
| References | 25428505 - Nature. 2014 Nov 27;515(7528):568-71 23258413 - Science. 2013 Feb 15;339(6121):786-91 20693853 - Cancer J. 2010 Jul-Aug;16(4):399-403 25320273 - J Immunol. 2014 Nov 15;193(10):4779-82 25517616 - Immunity. 2014 Nov 20;41(5):843-52 15454922 - Nat Immunol. 2004 Oct;5(10):987-95 22658127 - N Engl J Med. 2012 Jun 28;366(26):2443-54 1309851 - J Exp Med. 1992 Jan 1;175(1):139-46 19915919 - Ann Surg Oncol. 2010 Mar;17(3):718-30 25517615 - Immunity. 2014 Nov 20;41(5):830-42 23910378 - Cell. 2013 Aug 15;154(4):748-62 25409260 - N Engl J Med. 2014 Dec 4;371(23):2189-99 15381769 - Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14639-45 23752227 - J Exp Med. 2013 Jul 1;210(7):1389-402 18157142 - Nat Med. 2008 Jan;14(1):28-36 8791125 - Important Adv Oncol. 1996;:3-21 24382348 - J Clin Invest. 2014 Feb;124(2):687-95 24434209 - Cancer Cell. 2014 Jan 13;25(1):37-48 23585680 - J Immunol. 2013 May 15;190(10):5216-25 15778348 - J Immunol. 2005 Apr 1;174(7):3925-31 25029335 - N Engl J Med. 2014 Aug 7;371(6):507-18 25217157 - J Immunol. 2014 Oct 15;193(8):4254-60 22397654 - N Engl J Med. 2012 Mar 8;366(10):925-31 24829760 - J Immunother Cancer. 2014 Feb 18;2:3 25261479 - J Immunol. 2014 Nov 1;193(9):4634-42 17875753 - Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5256-61 25300616 - Nat Commun. 2014;5:5166 22426464 - Int J Mol Med. 2012 Jun;29(6):1153-7 17909797 - Cancer Immunol Immunother. 2008 May;57(5):685-91 16468035 - Cancer Immunol Immunother. 2006 Oct;55(10):1185-97 23724867 - N Engl J Med. 2013 Jul 11;369(2):122-33 10537273 - Cancer Res. 1999 Oct 15;59(20):5059-63 9190110 - Immunol Today. 1997 Jun;18(6):267-8 21436454 - Science. 2011 Mar 25;331(6024):1612-6 24264989 - Science. 2013 Nov 22;342(6161):967-70 23097687 - Sci Rep. 2012;2:765 19293190 - Cancer Res. 2009 Apr 1;69(7):3077-85 14704792 - Nat Immunol. 2004 Feb;5(2):141-9 18316622 - Cancer Res. 2008 Mar 1;68(5):1563-71 21941296 - Nat Rev Immunol. 2011 Oct;11(10):702-11 21930765 - J Exp Med. 2011 Sep 26;208(10):2005-16 23986400 - Sci Transl Med. 2013 Aug 28;5(200):200ra116 21709202 - J Clin Oncol. 2011 Aug 1;29(22):2965-71 18724357 - Nature. 2008 Oct 2;455(7213):674-8 25300859 - Cancer Immunol Res. 2014 Dec;2(12):1199-208 22146893 - Cancer Immunol Immunother. 2012 Jul;61(7):1019-31 17641063 - J Immunol. 2007 Aug 1;179(3):1960-8 12805336 - J Clin Oncol. 2003 Jun 15;21(12):2342-8 23132945 - Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19386-91 21930769 - J Exp Med. 2011 Sep 26;208(10):1989-2003 10702484 - Clin Diagn Lab Immunol. 2000 Mar;7(2):141-4 11748260 - J Clin Invest. 2001 Dec;108(12):1771-80 23747010 - Mol Cell. 2013 Jul 25;51(2):226-35 23579075 - Curr Opin Immunol. 2013 Apr;25(2):268-76 23122052 - Trends Immunol. 2013 Feb;34(2):67-73 12750277 - Cancer Res. 2003 May 15;63(10):2535-45 16972901 - Immunol Rev. 2006 Oct;213:131-45 19008445 - Science. 2008 Nov 14;322(5904):1097-100 15087405 - Cancer Res. 2004 Apr 15;64(8):2865-73 21300764 - Cancer Res. 2011 Apr 1;71(7):2488-96 22909381 - J Transl Med. 2012;10:170 22461641 - Sci Transl Med. 2012 Mar 28;4(127):127ra37 18020500 - BioDrugs. 1997 Aug;8(2):119-27 |
| References_xml | – reference: 23910378 - Cell. 2013 Aug 15;154(4):748-62 – reference: 8791125 - Important Adv Oncol. 1996;:3-21 – reference: 18316622 - Cancer Res. 2008 Mar 1;68(5):1563-71 – reference: 22397654 - N Engl J Med. 2012 Mar 8;366(10):925-31 – reference: 21300764 - Cancer Res. 2011 Apr 1;71(7):2488-96 – reference: 25029335 - N Engl J Med. 2014 Aug 7;371(6):507-18 – reference: 21930769 - J Exp Med. 2011 Sep 26;208(10):1989-2003 – reference: 23724867 - N Engl J Med. 2013 Jul 11;369(2):122-33 – reference: 22146893 - Cancer Immunol Immunother. 2012 Jul;61(7):1019-31 – reference: 20693853 - Cancer J. 2010 Jul-Aug;16(4):399-403 – reference: 16972901 - Immunol Rev. 2006 Oct;213:131-45 – reference: 24829760 - J Immunother Cancer. 2014 Feb 18;2:3 – reference: 25261479 - J Immunol. 2014 Nov 1;193(9):4634-42 – reference: 23579075 - Curr Opin Immunol. 2013 Apr;25(2):268-76 – reference: 17875753 - Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5256-61 – reference: 25300859 - Cancer Immunol Res. 2014 Dec;2(12):1199-208 – reference: 9190110 - Immunol Today. 1997 Jun;18(6):267-8 – reference: 16468035 - Cancer Immunol Immunother. 2006 Oct;55(10):1185-97 – reference: 22658127 - N Engl J Med. 2012 Jun 28;366(26):2443-54 – reference: 25409260 - N Engl J Med. 2014 Dec 4;371(23):2189-99 – reference: 15381769 - Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14639-45 – reference: 25517616 - Immunity. 2014 Nov 20;41(5):843-52 – reference: 15454922 - Nat Immunol. 2004 Oct;5(10):987-95 – reference: 22461641 - Sci Transl Med. 2012 Mar 28;4(127):127ra37 – reference: 25517615 - Immunity. 2014 Nov 20;41(5):830-42 – reference: 25300616 - Nat Commun. 2014;5:5166 – reference: 1309851 - J Exp Med. 1992 Jan 1;175(1):139-46 – reference: 15087405 - Cancer Res. 2004 Apr 15;64(8):2865-73 – reference: 21709202 - J Clin Oncol. 2011 Aug 1;29(22):2965-71 – reference: 23585680 - J Immunol. 2013 May 15;190(10):5216-25 – reference: 25428505 - Nature. 2014 Nov 27;515(7528):568-71 – reference: 21930765 - J Exp Med. 2011 Sep 26;208(10):2005-16 – reference: 23097687 - Sci Rep. 2012;2:765 – reference: 19293190 - Cancer Res. 2009 Apr 1;69(7):3077-85 – reference: 23986400 - Sci Transl Med. 2013 Aug 28;5(200):200ra116 – reference: 12805336 - J Clin Oncol. 2003 Jun 15;21(12):2342-8 – reference: 19915919 - Ann Surg Oncol. 2010 Mar;17(3):718-30 – reference: 23132945 - Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19386-91 – reference: 21436454 - Science. 2011 Mar 25;331(6024):1612-6 – reference: 24382348 - J Clin Invest. 2014 Feb;124(2):687-95 – reference: 25217157 - J Immunol. 2014 Oct 15;193(8):4254-60 – reference: 17909797 - Cancer Immunol Immunother. 2008 May;57(5):685-91 – reference: 22909381 - J Transl Med. 2012;10:170 – reference: 23258413 - Science. 2013 Feb 15;339(6121):786-91 – reference: 11748260 - J Clin Invest. 2001 Dec;108(12):1771-80 – reference: 23122052 - Trends Immunol. 2013 Feb;34(2):67-73 – reference: 18724357 - Nature. 2008 Oct 2;455(7213):674-8 – reference: 15778348 - J Immunol. 2005 Apr 1;174(7):3925-31 – reference: 25320273 - J Immunol. 2014 Nov 15;193(10):4779-82 – reference: 18020500 - BioDrugs. 1997 Aug;8(2):119-27 – reference: 12750277 - Cancer Res. 2003 May 15;63(10):2535-45 – reference: 24434209 - Cancer Cell. 2014 Jan 13;25(1):37-48 – reference: 23747010 - Mol Cell. 2013 Jul 25;51(2):226-35 – reference: 19008445 - Science. 2008 Nov 14;322(5904):1097-100 – reference: 22426464 - Int J Mol Med. 2012 Jun;29(6):1153-7 – reference: 23752227 - J Exp Med. 2013 Jul 1;210(7):1389-402 – reference: 18157142 - Nat Med. 2008 Jan;14(1):28-36 – reference: 14704792 - Nat Immunol. 2004 Feb;5(2):141-9 – reference: 21941296 - Nat Rev Immunol. 2011 Oct;11(10):702-11 – reference: 17641063 - J Immunol. 2007 Aug 1;179(3):1960-8 – reference: 10702484 - Clin Diagn Lab Immunol. 2000 Mar;7(2):141-4 – reference: 10537273 - Cancer Res. 1999 Oct 15;59(20):5059-63 – reference: 24264989 - Science. 2013 Nov 22;342(6161):967-70 |
| SSID | ssj0021722 |
| Score | 2.6114504 |
| SecondaryResourceType | review_article |
| Snippet | A growing body of evidence suggests that a major subset of patients with advanced solid tumors shows evidence for a T-cell-inflamed tumor microenvironment.... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 663 |
| SubjectTerms | Animals Humans Immunotherapy - methods Neoplasms - immunology Neoplasms - therapy T-Lymphocytes - immunology Tumor Microenvironment - immunology |
| Title | The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/26320069 https://www.proquest.com/docview/1708896265 |
| Volume | 42 |
| WOSCitedRecordID | wos000360782200014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7UinjxXa0vVvC6tEmzeXgRKZYWbOyhSm9hn1Bok5q2gv_emSRVL4LgJeQyJMx8O4-dFyG3UrW44DxgQhuPea4rmfRNyKz2IwUesPCLaZ-vT0Ech-NxNKwu3BZVWeVaJxaKWmcK78ibToAFOUDJ7-dvDLdGYXa1WqGxSWptcGUQ1cH4K4uAu5fW1TuAtSZ2cc8mEFUDi7Goi5czO53fncvCyHT3__t7B2Svci_pQ4mHQ7Jh0iOyM6gS6MdEAixoDAqZ9la5nho6SWkHBZ_TPnaKVP1YH3f0GTAOnwbLRpdIk6VsxDpmOmX91AKMjKaj1SzL6QBL-n70y52Ql-7jqNNj1ZoFpnCbAVMmlBAgc8u1AHfR1W0LQYfQIrTgPHiexJmFIFI_8lVLCgtG3hOOE0npc2ld7tbJFjDVnBGK6-ocFUhZ9M9FSrb9SCsZWQvv2mk1yM2aewnAGHMTIjXZapF8869BTksRJPNy3kaCI-VxovL5H6gvyC5KtizRuyQ1C4fYXJFt9b6cLPLrAh_wjIeDT8Fhx9U |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Next+Hurdle+in+Cancer+Immunotherapy%3A+Overcoming+the+Non-T-Cell-Inflamed+Tumor+Microenvironment&rft.jtitle=Seminars+in+oncology&rft.au=Gajewski%2C+Thomas+F&rft.date=2015-08-01&rft.eissn=1532-8708&rft.volume=42&rft.issue=4&rft.spage=663&rft.epage=671&rft_id=info:doi/10.1053%2Fj.seminoncol.2015.05.011&rft.externalDBID=NO_FULL_TEXT |